Monoclonal antibodies (mAbs) are widely used due to their exquisite specificity and once were hailed as the solution to cancer. However, when mouse mAbs are administered in humans, anti-antibody response (AAR) is frequently observed. Using humanized mAbs which are commonly developed by CDR-grafting method, the AAR is negligible, but loss of binding has also been consistently reported. Therefore, in an effort to produce humanized anti-C2 mAbs that retain binding properties but produce minimal AAR, humanized mAb has been developed by logical approach using IgBLAST. The purity and functionality of humanized mAb was confirmed by Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and cell-based assays, respectively. Although th...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Mil...
Two humanized monoclonal antibody constructs bearing the same variable regions of an anti-CD3 monocl...
Humanized monoclonal antibodies (mAbs) are widely used for diagnosis and treatment of cancer due to...
Human monoclonal antibodies (mAbs) are powerful tools as pharmaceutical agents to tackle cancer and ...
One of the major obstacles in the successful clinical application of monoclonal antibodies has been ...
Antibodies are the support of adaptive humoral immunity and they are characterized by their high div...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
Antibody therapy is being developed and tested as one of the most promising agents for treatment of ...
Monoclonal antibodies (mAbs) are a group of antibodies produced by identical clones of B lymphocytes...
International audienceBackground: There is an ever-increasing need of monoclonal antibodies (mAbs) f...
The use of serum containing polyclonal antibodies from animals immunized with toxins marked the begi...
10.1155/2013/716961Clinical and Developmental Immunology2013Article number 716961,6 page
''To whom correspondence should be addressed Mouse monoclonal anti-human IL-2 receptor ant...
Antibody humanization is a key step in the preclinical phase of the development of therapeutic antib...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Mil...
Two humanized monoclonal antibody constructs bearing the same variable regions of an anti-CD3 monocl...
Humanized monoclonal antibodies (mAbs) are widely used for diagnosis and treatment of cancer due to...
Human monoclonal antibodies (mAbs) are powerful tools as pharmaceutical agents to tackle cancer and ...
One of the major obstacles in the successful clinical application of monoclonal antibodies has been ...
Antibodies are the support of adaptive humoral immunity and they are characterized by their high div...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
Antibody therapy is being developed and tested as one of the most promising agents for treatment of ...
Monoclonal antibodies (mAbs) are a group of antibodies produced by identical clones of B lymphocytes...
International audienceBackground: There is an ever-increasing need of monoclonal antibodies (mAbs) f...
The use of serum containing polyclonal antibodies from animals immunized with toxins marked the begi...
10.1155/2013/716961Clinical and Developmental Immunology2013Article number 716961,6 page
''To whom correspondence should be addressed Mouse monoclonal anti-human IL-2 receptor ant...
Antibody humanization is a key step in the preclinical phase of the development of therapeutic antib...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Mil...
Two humanized monoclonal antibody constructs bearing the same variable regions of an anti-CD3 monocl...